The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.
 
Kyrillus Samaan Shohdy
No Relationships to Disclose
 
Dario Martin Villamar
No Relationships to Disclose
 
Yen Cao
No Relationships to Disclose
 
Janson Trieu
No Relationships to Disclose
 
Kristin Sedgwick Price
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Rebecca Nagy
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Ana M. Molina
Consulting or Advisory Role - Eisai; Eisai; Eisai; Exelixis; Janssen
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Foundation Medicine; Genzyme; Immunomedics; Incyte; Medscape; Merck; MSD; Pfizer; Roche; UroToday
 
David M. Nanus
Consulting or Advisory Role - AstraZeneca; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Genentech; GlaxoSmithKline; Guardant Health; Immunomedics; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Regeneron; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Guru P. Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; Pfizer; Scholar Rock; Seagen
Speakers' Bureau - Medscape; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; Debiopharm Group; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics
 
Juan Miguel Mosquera
Research Funding - Personal Genome Diagnostics
Travel, Accommodations, Expenses - Personal Genome Diagnostics
 
Olivier Elemento
Stock and Other Ownership Interests - OneThree Biotech; Owkin; Volastra Therapeutics
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Merck; Novartis; Pfizer; UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Myovant Sciences; on quality; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology
 
Bishoy Morris Faltas
Honoraria - Digital Science Press
Consulting or Advisory Role - Immunomedics; Immunomedics; Merck; QED Therapeutics; QED Therapeutics; Seagen; Seagen
Research Funding - Lilly